Semax and Selank were both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. They share the same C-terminal Pro-Gly-Pro stability extension. They have both been approved as prescription medications in Russia. And they are frequently discussed together as a pair.

But they come from completely different parent molecules, target completely different neurological systems, and produce qualitatively different effects in research models. Understanding these differences is essential for protocol design.

Semax: From a Stress Hormone

ACTH (adrenocorticotropic hormone) is the pituitary hormone that tells the adrenal glands to produce cortisol during stress. It's a 39-amino-acid molecule with multiple functional domains. Researchers discovered that the 4-10 fragment retained neurotrophic properties — the ability to support neuron growth and survival — without any adrenal-stimulating activity.¹

Semax was designed to exploit this separation. By isolating the neurotrophic domain and adding the Pro-Gly-Pro stability extension, the developers created a compound that promotes BDNF and NGF expression without triggering the stress response. It's an "activating" compound — it enhances the brain's capacity for growth and plasticity.

Selank: From an Immune Peptide

Tuftsin is a tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of immunoglobulin G. It's known for activating monocytes and natural killer cells. Selank adds the same Pro-Gly-Pro extension to tuftsin, creating a compound with both immune-modulating and neurological properties.²

The GABAergic effects were somewhat unexpected — tuftsin is an immune peptide, not a neurological one. But research showed that Selank modulated GABA-A receptor subunit gene expression in the hippocampus and amygdala, producing anxiolytic-like effects in animal behavioral models without sedation or tolerance.³

This is a "calming" compound — it reduces anxiety-like behavior by enhancing inhibitory neurotransmission in brain regions associated with fear and anxiety processing.

Research question: neuroplasticity, neuroprotection, or cognitive enhancement → Semax is the appropriate tool. Its BDNF/NGF upregulation directly supports neuronal growth, synaptic plasticity, and resilience to injury. The ischemia research (reduced infarct volume, improved functional outcomes) is well-documented.⁴

Research question: anxiety modulation, GABAergic pharmacology, or neuroimmunology → Selank is the appropriate tool. Its GABA-A subunit modulation and serotonin turnover effects are directly relevant to anxiety models. Its dual neuro/immune profile makes it valuable for studying the neuroimmune axis.⁵

Research question: comparing neurotrophic vs anxiolytic mechanisms → Both, side by side. Using Semax and Selank in the same protocol with the same model and endpoints allows direct comparison of BDNF-mediated vs GABA-mediated effects on shared outcome measures.

Research question: combined neurotrophic + anxiolytic effects → Both, administered together. Since they target non-overlapping pathways (BDNF/NGF vs GABA), combination protocols can investigate whether simultaneous neurotrophic and anxiolytic modulation produces complementary effects.

Despite their mechanistic differences, Semax and Selank share several properties:

No tolerance or dependence. Neither compound has shown tolerance development (requiring increasing doses for the same effect) or dependence (withdrawal symptoms upon discontinuation) in animal studies. This distinguishes them from benzodiazepines and stimulants.

Gene expression breadth. Both compounds modulate hundreds of genes in brain tissue, affecting pathways beyond their primary mechanisms. Both influence immune-related genes, vascular genes, and stress response genes.

Metabolic stability. The shared Pro-Gly-Pro extension gives both compounds improved resistance to enzymatic degradation, extending their activity window in biological systems.

Russian clinical history. Both have been through regulatory review in Russia, providing a level of clinical exposure that most research peptides lack. The limitations of the Russian evidence base (different regulatory standards, limited English-language publication) apply equally to both.